MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Inclusion Criteria: * Diagnosis of 1 of the following diseases by bone marrow aspiration and/or biopsy: * Myelodysplastic syndromes (MDS) meeting the following criteria: * Must have 1 of the following subtypes: * Refractory anemia (RA) (no RA with 5q-syndrome), * RA with ringed sideroblasts or * Refractory cytopenia with multilineage dysplasia * Myelodysplastic syndromes (MDS) meeting the following criteria: Must have 1 of the following subtypes: * Refractory cytopenia with multilineage dysplasia and ringed sideroblasts, * RA with excess blasts (RAEB)-1, RAEB-2, * Myelodysplastic syndromes, unclassified or * Chronic myelomonocytic leukemia * International Prognostic Scoring System score of intermediate-2 or high-risk * Acute myeloid leukemia (AML) meeting 1 of the following criteria: * Relapsed or refractory AML, including any of the following subtypes: * \* AML with recurrent cytogenetic abnormalities (i.e., AML with 11q23 \[MLL\] abnormalities) * AML with multilineage dysplasia * AML that is therapy-related * AML, not otherwise categorized (M0 \[minimally differentiated\], M1 \[without maturation\], M2 \[with maturation\], M4 \[myelomonocytic leukemia\], M5 \[monoblastic/monocytic leukemia\], M6 \[erythroid leukemia\], and M7 \[megakaryoblastic leukemia\]) * Untreated AML * Newly diagnosed patients are eligible provided they do not qualify for potentially curative intensive chemotherapeutic regimens * Acute lymphocytic leukemia (ALL) meeting 1 o…